Here are a few reasons to pick up a copy of The Guardian on Tuesday. Find these stories and much more when you grab a copy of The Guardian on Tuesday.⁣⁣⁣

We're not superheroes, we are scientists, BioNTech CEO Ugur Sahin has told DW. In an exclusive interview, the scientist explains how the firm will respond to a new virus strain and why he has not been vaccinated yet.

It is "highly likely" that BioNTech's coronavirus vaccine works against the variant detected in the UK, the company's CEO has said. If necessary, the German firm could also adapt the vaccine within six weeks.

The decision by European Medicines Agency may allow countries to begin vaccinating before the end of the year. The vaccine's approval was widely expected, as EU nations grapple with a worsening coronavirus second wave.

Here are a few reasons to pick up a copy of The Guardian on Thursday. Find these stories and much more when you grab a copy of The Guardian on Thursday.⁣

Pfizer and BioNTech have lodged their COVID-19 vaccine with the European Medicines Agency for conditional approval. The companies have already taken similar steps in the US and UK.

Moderna said that Phase 3 stage analysis suggested its coronavirus vaccine could prevent COVID-19. The news comes a week after Pfizer and German drug-maker BioNTech announced a vaccine of their own.

A vaccine jointly developed by German company BioNTech and US firm Pfizer has proven to be 90% effective at preventing COVID-19 infections, according to phase 3 trials.

Pfizer and BioNTech have chosen RNA messenger technology for their vaccine. It is made up of lab-made RNA strands containing the code for the same protein that allows coronavirus to enter cells.